
Cabaletta Bio CABA
€ 2.75
2.4%
Geschäftsbericht 2025
hinzugefügt 23.03.2026
Cabaletta Bio Langfristige Verbindlichkeiten 2011-2026 | CABA
Langfristige Verbindlichkeiten Jährlich Cabaletta Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 43.9 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 43.9 M | 43.9 M | 43.9 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
BioNTech SE
BNTX
|
341 M | $ 97.57 | 2.17 % | $ 27.2 B | ||
|
Aligos Therapeutics
ALGS
|
15 M | $ 8.49 | 6.25 % | $ 83.9 M | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.63 | -2.42 % | $ 8.73 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
355 M | $ 2.15 | -0.69 % | $ 447 M | ||
|
Evogene Ltd.
EVGN
|
5.36 M | $ 0.83 | 2.5 % | $ 27.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 20.87 | 2.45 % | $ 976 M | ||
|
Genmab A/S
GMAB
|
769 M | $ 28.23 | -0.07 % | $ 18 B | ||
|
Grifols, S.A.
GRFS
|
7.22 B | $ 8.24 | 0.3 % | $ 6.83 B | ||
|
GT Biopharma
GTBP
|
714 K | $ 0.37 | -0.92 % | $ 2.04 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Halozyme Therapeutics
HALO
|
388 M | $ 66.86 | -1.42 % | $ 8.01 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Harmony Biosciences Holdings
HRMY
|
149 M | $ 28.5 | -1.35 % | $ 1.64 B | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
168 M | $ 1.43 | 2.14 % | $ 368 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.91 | -0.26 % | $ 4.79 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.18 | 2.45 % | $ 447 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 23.96 | -1.03 % | $ 3.05 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
17.3 M | $ 32.21 | -0.09 % | $ 2.14 B | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.49 | -0.34 % | $ 397 M | ||
|
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | ||
|
Incyte Corporation
INCY
|
315 M | $ 94.65 | -1.48 % | $ 18.5 B | ||
|
Cidara Therapeutics
CDTX
|
942 K | - | - | $ 1.41 B | ||
|
Innate Pharma S.A.
IPHA
|
105 M | $ 1.48 | 4.61 % | $ 235 M | ||
|
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.57 | 0.78 % | $ 16.1 M | ||
|
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B | ||
|
Inventiva S.A.
IVA
|
13.8 M | $ 5.15 | -2.09 % | $ 138 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B |